Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 Genitourinary Cancers Symposium /
Comment: Urothelial cancer research from ASCO GU 2018

8th - 10th Feb 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.02.18
Views: 658
Rating:

Dr Guru Sonpavde - Dana-Farber Cancer Institute, Boston, USA

Dr Sonpavde speaks with ecancer at the 2018 ASCO Genitourinary Cancers Symposium to comment on two bladder cancer studies presented at the meeting.

He starts with the POUT trial which looked at adjuvant cisplatin based chemotherapy in upper tract urothelial carcinoma post nephroureterectomy which achieved the clinical outcome efficacy endpoint. 

To hear more about this, watch the interview with Dr Alison Birtle here.

The second study looked at the addition of a new 6-factor prognostic model for patients with advanced urothelial carcinoma.

For more on this model, watch the interview with Dr Gregory Pond here.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation